IP Library Patent Application 13033887
Patent Application
App. No. 13/033,887

LENS CARE SOLUTIONS FUNCTIONALIZED ALKYLDIMONIUM HYDROXYPROPYL ALKYLGLUCOSIDES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/033,887
Abstract

A contact lens care solution that includes a functionalized hydroxypropyl alkylglucoside. The functionalized hydroxypropyl alkylglucoside is typically in the form a mixture of various alkylglycosides because: (1) the functional reagents can react with any one or more of the many hydroxyl groups on the glycoside; and (2) the glycosides are present as a mixture of glycosides with a degree of polymerization from 1 to about 4. The solution will also include a buffer system to maintain the pH of the composition from 7.2 to 8.5. In particular, the solution can be formulated to clean and disinfect contact lenses or the solution is formulated as a rewet eye drop for use with contact lenses.

Claims (52)

1 . A contact lens care solution comprising one or more functionalized hydroxypropyl alkylglucosides that are prepared by a process of reacting a mixture of at least the alkylglycosides A and B

wherein R is alkyl having 8 to 16 carbon atoms

with a polymerizing agent ClCH 2 CH(OH)CH 2 Cl and a functionalized hydroxypropyl agent selected from the group consisting of

wherein R 1 is CH 3 (CH 2 ) n and n is an integer ranging from 6 to 16, and LG is a common leaving group, in an aqueous medium at a temperature of 80° C. to 120° C. for 4 to 12 hours; and

a buffer system to maintain the pH of the composition from 7.2 to 8.5.

2 . The lens care solution of claim 1 wherein the functionalized hydroxypropyl agent is selected from

to provide a functionalized alkylglycoside product mixture including a functionalized alkyldimonium hydroxypropyl alkylglucoside selected from the group consisting of

stearyldimoniumhydroxypropyl laurylglucosides chloride,

stearyldimoniumhydroxypropyl laurylglucosides chloride,

stearyldimoniumhydroxypropyl decylglucosides chloride,

lauryldimoniumhydroxypropyl laurylglucosides chloride, and

lauryldimoniumhydroxypropyl decylglucosides chloride.

3 . The lens care solution of claim 1 wherein the functionalized hydroxypropyl agent is selected from

to provide a functionalized alkylglycoside product mixture including a functionalized alkyldimonium hydroxypropyl alkylglucoside selected from the group consisting of

poly(stearyldimonium hydroxypropyl laurylglucosides chloride,

poly(stearyldimonium hydroxypropyl decylglucosides chloride,

poly(lauryldimonium hydroxypropyl laurylglucosides chloride,

poly(lauryldimonium hydroxypropyl decylglucosides chloride,

poly(trimonium hydroxypropyl laurylglucosides chloride and

poly(trimonium hydroxypropyl decylglucosides chloride.

4 . The lens care solution of claim 1 wherein the functionalized hydroxypropyl alkylglucoside is present in the solution from 0.001% to 0.05% by weight.

5 . The lens care solution of claim 2 wherein the one or more functionalized alkyldimonium hydroxypropyl alkylglucoside includes stearyldimonium hydropropyl laurylglucoside.

6 . The lens care solution of claim 2 wherein the one or more functionalized alkyldimonium hydroxypropyl alkylglucoside includes stearyldimonium hydropropyl decylglucoside.

7 . The lens care solution of claim 1 further comprising poly(hexamethylene biguanide) at a concentration from 0.05 ppm to 2 ppm.

8 . The lens care solution of claim 1 further comprising polyquaternium-1 at a concentration from 1 ppm to 10 ppm.

9 . The lens care solution of claim 7 further comprising polyquaternium-1 at a concentration from 1 ppm to 3 ppm.

10 . The lens care solution of claim 1 wherein the functionalized hydroxypropyl agent is selected from

to provide a functionalized alkylglycoside product mixture comprising the functionalized hydroxypropyl alkylglucoside formulas I and III

11 . The lens care solution of claim 1 wherein the functionalized hydroxypropyl agent is selected from

to provide a functionalized alkylglycoside product mixture comprising the functionalized hydroxypropyl alkylglucoside formulas II and IV

12 . The lens care solution of claim 1 further comprising a comfort agent selected from the group consisting of propylene glycol, hydroxypropylmethyl cellulose, hydroxylpropyl guar and hyaluronic acid.

13 . The lens care solution of claim 1 wherein the comfort agent is hyaluronic acid.

14 . A contact lens care solution comprising one or more functionalized hydroxypropyl alkylglucosides that are prepared by a process of reacting a mixture of at least the alkylglycosides A and B

wherein R is alkyl having 8 to 16 carbon atoms

with a polymerizing agent ClCH 2 CH(OH)CH 2 Cl and a functionalized hydroxypropyl agent selected from the group consisting of:

wherein R 1 is CH 3 (CH 2 ) n and n is an integer ranging from 6 to 16, and LG is a common leaving group, in an aqueous medium at a temperature of 80° C. to 120° C. for 4 to 12 hours;

0.5 to 15 ppm of polyquaternium-1; and

a buffer system to maintain the pH of the composition from 7.2 to 8.5.

15 . The lens care solution of claim 14 wherein the functionalized hydroxypropyl agent is selected from

to provide a functionalized alkylglycoside product mixture comprising the functionalized hydroxypropyl alkylglucoside formulas I and III

16 . The lens care solution of claim 14 wherein the functionalized hydroxypropyl agent is selected from

to provide a functionalized alkylglycoside product mixture comprising the functionalized hydroxypropyl alkylglucoside formulas II and IV

17 . A contact lens care solution comprising one or more functionalized hydroxypropyl alkylglucosides that are prepared by a process of reacting a mixture of at least the alkylglycosides A and B

wherein R is alkyl having 8 to 16 carbon atoms

with a polymerizing agent ClCH 2 CH(OH)CH 2 Cl and a functionalized hydroxypropyl agent selected from the group consisting of:

wherein R 1 is CH 3 (CH 2 ) n and n is an integer ranging from 6 to 16, and LG is a common leaving group, in an aqueous medium at a temperature of 80° C. to 120° C. for 4 to 12 hours;

0.5 to 2 ppm of poly(hexamethylene biguanide); and

a buffer system to maintain the pH of the composition from 7.2 to 8.5.

18 . The lens care solution of claim 17 wherein the functionalized hydroxypropyl agent is selected from

to provide a functionalized alkylglycoside product mixture comprising the functionalized hydroxypropyl alkylglucoside formulas I and III

19 . The lens care solution of claim 17 wherein the functionalized hydroxypropyl agent is selected from

to provide a functionalized alkylglycoside product mixture comprising the functionalized hydroxypropyl alkylglucoside formulas II and IV

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2011
From: XIA, ERNING; MILLARD, KIMBERLY
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 025859/0556 →